- Fellowship - Jackson Memorial Hospital (1991-1993), Endocrinology & Metabolism
- Internship - Jackson Memorial Hospital (1988-1991), Internal Medicine
- Medical School - Emory University School of Medicine (1984-1988)
Luigi Meneghini, M.D.
- Internal Medicine - Endocrinology
Luigi Meneghini, M.D., M.B.A., is a Professor of Internal Medicine at the University of Texas Southwestern Medical Center, Division of Endocrinology, in Dallas, Texas, and Executive Director of the Parkland Health and Hospital System Global Diabetes Program. He recently joined UT Southwestern after a 20-year tenure at the University of Miami Miller School of Medicine where he was Professor of Clinical Medicine and Director of the Kosow Diabetes Treatment Center.
Dr. Meneghini’s primary interests lie in improving the lives of patients with diabetes through the application of cutting edge therapies and technologies, and the implementation of these treatment strategies through patient and professional education activities. He has been involved in the development of treatment algorithms for glycemic control of type 1 and type 2 diabetes. At UT Southwestern he is charged with implementing a registry based chronic care model and exploring opportunities for leveraging this infrastructure to optimize population-based health management and translational research.
Dr. Meneghini is a frequent lecturer and has published numerous articles in peer-reviewed medical journals. He has presented numerous projects at the Scientific Sessions of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). He is a native of Italy and speaks Italian, French, English, and Spanish fluently. While he thoroughly enjoys a good laugh, especially over a good meal and bottle of wine, the greatest love of his life is his wife and family.
- Texas Medical Association (2013), Member
- Endocrine Society (2013), Member
- Dallas County Medical Society (2013), Member
- American Diabetes Association (2013), Member
- American Association of Clinical Endocrinologists (2013), Member
Pathophysiology of Type 1 Diabetes in Type 1 Diabetes in Adults: Principles and Practices
Meneghini LF (2008), New York, NY, Informa Healthcare USA
- Pathophysiology of Type 1 Diabetes in Type 1 Diabetes in Adults: Principles and Practices
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI Diabetes care 2013 Apr 36 4 858-64
Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.
Freemantle N, Meneghini L, Christensen T, Wolden ML, Jendle J, Ratner R Diabetic medicine : a journal of the British Diabetic Association 2013 Feb 30 2 226-32
Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.
Umpierrez GE, Meneghini L Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2013 Jul-Aug 19 4 718-28
Intensifying insulin therapy: what options are available to patients with type 2 diabetes?
Meneghini LF The American journal of medicine 2013 Sep 126 9 Suppl 1 S28-37
Insulin stacking versus therapeutic accumulation: understanding the differences.
Heise T, Meneghini LF Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2014 Jan-Feb 20 1 75-83
Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities.
Brod M, Alolga SL, Meneghini L The patient 2014 Jun
Early insulin treatment in type 2 diabetes: what are the pros?
Meneghini LF Diabetes care 2009 Nov 32 Suppl 2 S266-9
Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P Diabetes, obesity & metabolism 2013 Aug 15 8 729-36
The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF Diabetes, obesity & metabolism 2012 Jul
Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.
Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2011 Sep-Oct 17 5 727-36
- The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
- Use of technologies for glycemic control
- Insulin replacement for glycemic control
- Impact of education on diabetes self-management